Juan Monteverde, founder and managing partner of the class action firm About Monteverde & Associates PC
Monteverde & Associates PC
(the“M&A Class Action Firm”), a national securities firm rated
in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the
Empire State Building
New York City, is investigating
relating to its proposed merger with Elicio Therapeutics. Under the terms of the agreement, Elicio shareholders are expected to receive new shares of ANGN, with ANGN shareholders expected to own approximately 34.5% of the combined company.
We are a national class action securities litigation law firm that has recovered millions of dollars and is committed to protecting shareholders from corporate wrongdoing. We were listed in the
in the 2018-2021 ISS Securities Class Action Services Report. Our lawyers have significant experience litigating Mergers & Acquisitions and Securities Class Actions. Mr. Monteverde is recognized by Super Lawyers in 2013 and 2017-2019 as a
Rising Star and in 2022 as a Super Lawyer in Securities Litigation. He has also been selected by
Martindale-Hubbell as a 2017-2021 Top Rated Lawyer. Our firm's recent successes include changing the law in a significant victory that lowered the standard of liability under Section 14(e) of the Exchange Act in the Ninth Circuit. Thereafter, our firm successfully preserved this victory by obtaining dismissal of a writ of certiorari as improvidently granted at the United States Supreme Court.
Emulex Corp. v. Varjabedian, 139 S. Ct. 1407 (2019). Also, we have recovered or secured over a dozen cash common funds for shareholders in mergers & acquisitions class action cases.
If you own common stock in ANGN and wish to obtain additional information and protect your investments free of charge, please visit our
Juan E. Monteverde, Esq.
either via e-mail at
or by telephone at (212) 971-1341.
Juan E. Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. Suite 4405
New York, NY
United States of America
Tel: (212) 971-1341
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.